The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

Diabetic kidney disease is the leading cause of kidney failure worldwide; in the USA, it
accounts for over 50% of individuals entering dialysis or transplant programmes. Unlike …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

Background The inflammatory response occurring in acute myocardial infarction (AMI) has
been proposed as a potential pharmacological target. Sodium-glucose co-transporter 2 …

Chronic kidney disease (CKD) is a chronic renal dysfunction syndrome that is characterized
by nephron loss, inflammation, myofibroblasts activation, and extracellular matrix (ECM) …

Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for
treatment of diabetes, have been shown to possess a favorable metabolic profile and to …